198 related articles for article (PubMed ID: 20179909)
1. Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.
Barak S; Weiner I
Psychopharmacology (Berl); 2010 Apr; 209(2):175-84. PubMed ID: 20179909
[TBL] [Abstract][Full Text] [Related]
2. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
[TBL] [Abstract][Full Text] [Related]
3. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
Barak S; Weiner I
Neuropsychopharmacology; 2007 May; 32(5):989-99. PubMed ID: 16971898
[TBL] [Abstract][Full Text] [Related]
4. Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered.
Gaisler-Salomon I; Diamant L; Rubin C; Weiner I
Psychopharmacology (Berl); 2008 Feb; 196(2):255-67. PubMed ID: 17928997
[TBL] [Abstract][Full Text] [Related]
5. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
Weiner I
Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500
[TBL] [Abstract][Full Text] [Related]
6. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Gaisler-Salomon I; Weiner I
Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
[TBL] [Abstract][Full Text] [Related]
8. Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli.
Barak S; Weiner I
Neuropsychopharmacology; 2010 Apr; 35(5):1073-82. PubMed ID: 20072122
[TBL] [Abstract][Full Text] [Related]
9. Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.
Arad M; Weiner I
Neuropsychopharmacology; 2010 Oct; 35(11):2179-92. PubMed ID: 20613719
[TBL] [Abstract][Full Text] [Related]
10. Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
Zuckerman L; Rimmerman N; Weiner I
Psychopharmacology (Berl); 2003 Sep; 169(3-4):298-307. PubMed ID: 12827344
[TBL] [Abstract][Full Text] [Related]
11. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment.
Weiner I; Arad M
Behav Brain Res; 2009 Dec; 204(2):369-86. PubMed ID: 19433114
[TBL] [Abstract][Full Text] [Related]
12. Critical role of CA1 muscarinic receptors on memory acquisition deficit induced by total (TSD) and REM sleep deprivation (RSD).
Javad-Moosavi BZ; Vaezi G; Nasehi M; Haeri-Rouhani SA; Zarrindast MR
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):128-135. PubMed ID: 28571775
[TBL] [Abstract][Full Text] [Related]
13. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.
Black MD; Varty GB; Arad M; Barak S; De Levie A; Boulay D; Pichat P; Griebel G; Weiner I
Psychopharmacology (Berl); 2009 Jan; 202(1-3):385-96. PubMed ID: 18709358
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine.
Meshulam Y; Cohen G; Chapman S; Alkalai D; Levy A
J Appl Toxicol; 2001 Dec; 21 Suppl 1():S75-8. PubMed ID: 11920924
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D1 receptor involvement in latent inhibition and overshadowing.
Nelson AJ; Thur KE; Cassaday HJ
Int J Neuropsychopharmacol; 2012 Nov; 15(10):1513-23. PubMed ID: 22176724
[TBL] [Abstract][Full Text] [Related]
16. The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.
Dawson GR; Bentley G; Draper F; Rycroft W; Iversen SD; Pagella PG
Pharmacol Biochem Behav; 1991 Aug; 39(4):865-71. PubMed ID: 1763105
[TBL] [Abstract][Full Text] [Related]
17. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine.
Matsuoka N; Aigner TG
J Pharmacol Exp Ther; 1997 Mar; 280(3):1201-9. PubMed ID: 9067304
[TBL] [Abstract][Full Text] [Related]
18. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats.
Shannon HE; Bemis KG; Hendrix JC; Ward JS
J Pharmacol Exp Ther; 1990 Dec; 255(3):1071-7. PubMed ID: 2262893
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a combination of physostigmine and scopolamine as pretreatment against the behavioural effects of organophosphates in the common marmoset (Callithrix jacchus).
Muggleton NG; Bowditch AP; Crofts HS; Scott EA; Pearce PC
Psychopharmacology (Berl); 2003 Mar; 166(3):212-20. PubMed ID: 12589520
[TBL] [Abstract][Full Text] [Related]
20. Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action.
Weiner I; Schiller D; Gaisler-Salomon I
Neuropsychopharmacology; 2003 Mar; 28(3):499-509. PubMed ID: 12629529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
